The March 29 press release and accompanying 8-K look pretty encouraging to me. If this funding agreement is completed as anticipated in the next couple of weeks, things should get much more interesting for VODG. I think it is reasonable to assume there will a noticeable increase in corporate news flow and investor relations types of activities going forward. At a minimum there could be some interesting trading opportunities (spikes, swings, or semi-sustained movements higher).
Based on the information in the 8-K, it appears Jim Musick will step aside as CEO (his new role will be President, Chief Scientific Officer, and Director). It is not entirely clear from the language in the filing if William Becker will take over as the new CEO of VODG, or whether they have plans to bring in another person. Becker is listed as the CEO of VODG's new subsidiary in the signatures part of the 8-K, but the filing doesn't specifically identify who will be the new VODG CEO.
Musick will convert all of the $2.3M debt (accrued compensation and advances) he is owed into 14M common shares. That works out be about .164 per share.
Interesting to note that according to the stem cell lab development agreement that VODG has established with DaVinci Centre, there are existing Institutional Review Board approvals for two clinical trials. Also, DaVinci will assist in the development/marketing of nutraceutical products......
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.